Novavax Reports Fourth Quarter and Full Year 2019 Financial Results
Voy leyendo y pegando lo importante:
NanoFlu™ Program
- Results of the pivotal Phase 3 clinical trial for NanoFlu, Novavax’ recombinant quadrivalent seasonal influenza vaccine candidate, are expected later this month
Initiation of Phase I clinical testing is expected in May or June
- Earlier today, Novavax announced a commercial license agreement related to its Matrix-M vaccine adjuvant. Matrix-M is a key component of Serum Institute of India’s malaria vaccine candidate, which it licensed from Jenner Institute at Oxford University. The vaccine candidate is currently in a Phase 2b clinical trial being conducted in Burkina Faso with top-line data expected in the second quarter of 2020.
As of December 31, 2019, Novavax had $82.2 million in cash, cash equivalents, marketable securities and restricted cash
- Through utilization of At-the-market (ATM) offerings during the fourth quarter of 2019, Novavax raised net proceeds of $30 million. For the twelve months of 2019, Novavax raised net proceeds of $97 million. Subsequent to year-end, through March 6, 2020, Novavax raised additional net proceeds of $156
net loss of $31.8 million, or $1.13 per share, for the fourth quarter of 2019
For the twelve months ended December 31, 2019, the net loss was $132.7 million, or $5.51 per share
Novavax revenue in the fourth quarter of 2019 was $8.8 million, compared to $6.1 million in the same period in 2018. This 44% increase was driven by $7.5 million in revenue for the recovery of additional costs under the closeout of the HHS BARDA
FIN
«Después de nada, o después de todo/ supe que todo no era más que nada.»